Morgan Stanley Initiates Coverage On Tandem Diabetes Care with Equal-Weight Rating, Announces Price Target of $45
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley has initiated coverage on Tandem Diabetes Care with an Equal-Weight rating and set a price target of $45.
August 22, 2024 | 10:23 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley has initiated coverage on Tandem Diabetes Care with an Equal-Weight rating and a price target of $45, indicating a neutral stance on the stock.
The initiation of coverage by Morgan Stanley with an Equal-Weight rating suggests a neutral outlook on Tandem Diabetes Care. The price target of $45 provides a specific valuation expectation, which may influence investor sentiment but does not suggest a strong buy or sell signal.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100